Articles Tagged With: relugolix
-
New Treatments for Uterine Fibroids
In this prospective, open-label, single-arm trial of 149 individuals with heavy menstrual bleeding and uterine leiomyomas, daily relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) resulted in a mean menstrual blood loss reduction of 90%, and 70% of the participants achieved amenorrhea by the end of the 52-week period. Similar results were found for other arms of the trial among women who crossed over from placebo and relugolix-only therapy to relugolix combination therapy.
-
Relugolix Tablets (Orgovyx)
Relugolix should be prescribed to adults with advanced prostate cancer.